Express Scripts Holding Co. | 2013 | FY | 3


14. Quarterly financial data (unaudited)
The following is a presentation of our unaudited quarterly financial data:
 
Quarters
(in millions, except per share data)
First
 
Second
 
Third
 
Fourth
Fiscal 2013(1)
 
 
 
 
 
 
 
Total revenues(2)
$
26,019.9

 
$
26,381.9

 
$
25,915.6

 
$
25,781.4

Cost of revenues(2)
24,057.8

 
24,266.8

 
23,921.4

 
23,720.4

Gross profit
1,962.1

 
2,115.1

 
1,994.2

 
2,061.0

Selling, general and administrative
1,119.0

 
1,110.8

 
1,118.7

 
1,232.2

Operating income
843.1

 
1,004.3

 
875.5

 
828.8

Net income from continuing operations
380.0

 
574.4

 
453.6

 
518.3

Net loss from discontinued operations, net of tax
(1.9
)
 
(23.9
)
 
(15.5
)
 
(12.3
)
Net income
$
378.1

 
$
550.5

 
$
438.1

 
$
506.0

Less: Net income attributable to non-controlling interest
5.1

 
7.5

 
11.4

 
4.1

Net income attributable to Express Scripts
373.0

 
543.0

 
426.7

 
501.9

Basic earnings (loss) per share
 
 
 
 
 
 
 
Continuing operations attributable to Express Scripts
$
0.46

 
$
0.70

 
$
0.55

 
$
0.65

Discontinued operations attributable to Express Scripts

 
(0.03
)
 
(0.02
)
 
(0.02
)
Net earnings attributable to Express Scripts
0.46

 
0.67

 
0.53

 
0.63

Diluted earnings (loss) per share attributable to Express Scripts
 
 
 
 
 
 
 
Continuing operations attributable to Express Scripts
$
0.45

 
$
0.68

 
$
0.54

 
$
0.64

Discontinued operations attributable to Express Scripts

 
(0.03
)
 
(0.02
)
 
(0.02
)
Net earnings attributable to Express Scripts
0.45

 
0.66

 
0.52

 
0.63

Amounts attributable to Express Scripts shareholders:
 
 
 
 
 
 
 
Income from continuing operations, net of tax
$
374.9

 
$
566.9

 
$
442.2

 
$
514.2

Discontinued operations, net of tax
(1.9
)
 
(23.9
)
 
(15.5
)
 
(12.3
)
Net income attributable to Express Scripts shareholders
$
373.0

 
$
543.0

 
$
426.7

 
$
501.9

 
Quarters
(in millions, except per share data)
First
 
Second(3)
 
Third
 
Fourth
Fiscal 2012(1)
 
 
 
 
 
 
 
Total revenues(2)
$
12,132.6

 
$
27,455.0

 
$
26,761.6

 
$
27,365.1

Cost of revenues(2)
11,300.6

 
25,375.7

 
24,658.7

 
25,067.4

Gross profit
832.0

 
2,079.3

 
2,102.9

 
2,297.7

Selling, general and administrative
265.1

 
1,579.9

 
1,282.2

 
1,390.8

Operating income
566.9

 
499.4

 
820.7

 
906.9

Net income from continuing operations
270.2

 
152.2

 
415.9

 
524.1

Net income (loss) from discontinued operations, net of tax

 
0.8

 
(20.0
)
 
(13.1
)
Net income
$
270.2

 
$
153.0

 
$
395.9

 
$
511.0

Less: Net income attributable to non-controlling interest
2.4

 
3.4

 
4.5

 
6.9

Net income attributable to Express Scripts
267.8

 
149.6

 
391.4

 
504.1

Basic earnings (loss) per share
 
 
 
 
 
 
 
Continuing operations attributable to Express Scripts
$
0.55

 
$
0.18

 
$
0.51

 
$
0.63

Discontinued operations attributable to Express Scripts

 

 
(0.02
)
 
(0.02
)
Net earnings attributable to Express Scripts
0.55

 
0.19

 
0.48

 
0.62

Diluted earnings (loss) per share attributable to Express Scripts
 
 
 
 
 
 
 
Continuing operations attributable to Express Scripts
$
0.55

 
$
0.18

 
$
0.50

 
$
0.62

Discontinued operations attributable to Express Scripts

 

 
(0.02
)
 
(0.02
)
Net earnings attributable to Express Scripts
0.55

 
0.18

 
0.47

 
0.61

Amounts attributable to Express Scripts shareholders:
 
 
 
 
 
 
 
Income from continuing operations, net of tax
$
267.8

 
$
148.8

 
$
411.4

 
$
517.2

Discontinued operations, net of tax

 
0.8

 
(20.0
)
 
(13.1
)
Net income attributable to Express Scripts shareholders
$
267.8

 
$
149.6

 
$
391.4

 
$
504.1


(1)
Adjusted to reflect the results of our acute infusion therapies line of business as discontinued.
(2)
Includes retail pharmacy co-payments of $3,674.4 and $1,496.6 for the three months ended March 31, 2013 and 2012, respectively, $3,204.3 and $3,519.1 for the three months ended June 30, 2013 and 2012, respectively, $2,966.5 and $3,348.9 for the three months ended September 30, 2013 and 2012, respectively, and $2,775.1 and $3,304.0 for the three months ended December 31, 2013 and 2012, respectively.
(3)
Includes the April 2, 2012 acquisition of Medco.

us-gaap:QuarterlyFinancialInformationTextBlock